Floatz logo

Capmatinib

Haematological Malignancy

Cancer Research UKSmall moleculePhase 2/3Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
89/ 100

Competitive context

136 Active assets in the Haematological Malignancy cohort.

Asset / SponsorPhaseRating
Inno-206
OHSU Knight Cancer Institute
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BBB
DEXAMETHASONE
City of Hope Medical Center
Phase 3BB
Teclistamab
Janssen Pharmaceutical K.K.
Phase 2BB
Bortezomib
OHSU Knight Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

Capmatinib is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
59 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
55 / 100
View asset →
hepatocellular carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →